follow the breadcrumb trail you know i really hope
Post# of 155584
(Total Views: 984)
Posted On: 07/23/2022 2:17:48 PM
follow the breadcrumb trail you know i really hope the new people connected with cydy are working for shareholders and there are no ulterior motives thus giving the store away!
Pitt5 minutes ago
Another GSK and CYDY connection bread crumb.
So I found some interesting info on Dr Brunke she's a dark horse on the board. Not much is known about her. Heres two things I find as bread crumbs.
One- Brunke has had primary responsibility for negotiating multiple partnerships and licenses, including with MedImmune and Astellas, and assisted in closing a deal with GlaxoSmithKline, among others. Dr. Brunke received her BA degree in Biochemistry as well as PhD in Microbiology from the University of Pennsylvania.
Two- Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo EU S.p.A., the wholly owned ltalian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A., which closed its financing in July 2021 for gross proceeds of approximately 8,830,000 euros.
So she's brought a small pharma to GSK in a merger. And she's familiar with a drug that helps stop diarrhea in HIV/AIDS patients.
Her husband Dr as well has a very extensive background as a CEO and numerous deals. He brought one to Glaxo.
Here's some stuff
Prior to Threshold, Barry co-founded and was CEO and Chairman of Camitro, a venture capital backed drug discovery technology company with teams in California and Cambridge, UK, which was acquired 2 years after its founding. Before Camitro, Barry was at Affymax Research Institute, which was acquired by Glaxo Wellcome, plc as its drug discovery technology development center and where Barry was Vice President of Research, responsible for technology development and drug discovery. Prior to Affymax, Barry was at Protein Design Labs (PDL) and Anergen. As a bench scientist at PDL, he co-invented the technology underlying fully humanized antibody therapeutics and applied that to daclizumab (Zenapax), the first FDA-approved fully humanized antibody therapeutic, that was licensed to and commercialized by Roche for the prevention of kidney transplant rejection. This technology has contributed to more than 15 FDA approved therapeutics with cumulative revenues in excess of $200B. Throughout his career, Barry has been a member of the Boards of Directors of a dozen both early stage venture capital-backed as well as public biotech companies and Chairman and/or Lead Director of 9 of those.
So her husband invited the first humanized anti body and was CEO of a company the specialized in finding small drug that work and bringing them to market. That company was bought by Glaxo before it became GSK. He has direct involvement to bringing over 15 humanized antibodies to market with a combined revenue of 200 billion. Sounds like he's really a good mentor to his wife that's on our board.
If you remember NP never wanted to sell CYDY/Leronlimab he wanted to go it alone and be big pharma. So upon NPs departure Dr Kelly either stepped away from the board president position out of solidarity to NP or was asked to step down and be replaced by Tanya from other board members. It may be based on that a majority of the board members know the NDAs are buyout offers and don't want to lock CYDY into only agreeing to a partnership scenario. They might all agree if the offer is right for a buyout why not entertain it. So when NP was approached by Dr Madden to be CEO they had an agreement NP would never let Big Pharma buy Cydy but would do a partnership. Now that he's gone and Kelly is not board president now so all options are on the table.
Pitt5 minutes ago
Another GSK and CYDY connection bread crumb.
So I found some interesting info on Dr Brunke she's a dark horse on the board. Not much is known about her. Heres two things I find as bread crumbs.
One- Brunke has had primary responsibility for negotiating multiple partnerships and licenses, including with MedImmune and Astellas, and assisted in closing a deal with GlaxoSmithKline, among others. Dr. Brunke received her BA degree in Biochemistry as well as PhD in Microbiology from the University of Pennsylvania.
Two- Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo EU S.p.A., the wholly owned ltalian subsidiary of Napo Pharmaceuticals, focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A., which closed its financing in July 2021 for gross proceeds of approximately 8,830,000 euros.
So she's brought a small pharma to GSK in a merger. And she's familiar with a drug that helps stop diarrhea in HIV/AIDS patients.
Her husband Dr as well has a very extensive background as a CEO and numerous deals. He brought one to Glaxo.
Here's some stuff
Prior to Threshold, Barry co-founded and was CEO and Chairman of Camitro, a venture capital backed drug discovery technology company with teams in California and Cambridge, UK, which was acquired 2 years after its founding. Before Camitro, Barry was at Affymax Research Institute, which was acquired by Glaxo Wellcome, plc as its drug discovery technology development center and where Barry was Vice President of Research, responsible for technology development and drug discovery. Prior to Affymax, Barry was at Protein Design Labs (PDL) and Anergen. As a bench scientist at PDL, he co-invented the technology underlying fully humanized antibody therapeutics and applied that to daclizumab (Zenapax), the first FDA-approved fully humanized antibody therapeutic, that was licensed to and commercialized by Roche for the prevention of kidney transplant rejection. This technology has contributed to more than 15 FDA approved therapeutics with cumulative revenues in excess of $200B. Throughout his career, Barry has been a member of the Boards of Directors of a dozen both early stage venture capital-backed as well as public biotech companies and Chairman and/or Lead Director of 9 of those.
So her husband invited the first humanized anti body and was CEO of a company the specialized in finding small drug that work and bringing them to market. That company was bought by Glaxo before it became GSK. He has direct involvement to bringing over 15 humanized antibodies to market with a combined revenue of 200 billion. Sounds like he's really a good mentor to his wife that's on our board.
If you remember NP never wanted to sell CYDY/Leronlimab he wanted to go it alone and be big pharma. So upon NPs departure Dr Kelly either stepped away from the board president position out of solidarity to NP or was asked to step down and be replaced by Tanya from other board members. It may be based on that a majority of the board members know the NDAs are buyout offers and don't want to lock CYDY into only agreeing to a partnership scenario. They might all agree if the offer is right for a buyout why not entertain it. So when NP was approached by Dr Madden to be CEO they had an agreement NP would never let Big Pharma buy Cydy but would do a partnership. Now that he's gone and Kelly is not board president now so all options are on the table.
(16)
(0)